

XOLREMDI (mavorixafor)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 12 years of age or older

Diagnosis

Patient must have the following:

WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)

AND ALL of the following:

- a. Patient has a genotype-confirmed variant of CXCR4 consistent with WHIM syndrome
- b. Absolute neutrophil count (ANC) ≤ 400 cells/µL
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Xolremdi and for 3 weeks after the last dose

Prior - Approval Limits

Quantity 400 mg per day

Duration 12 months

Prior - Approval Renewal Requirements

Age 12 years of age or older

Diagnosis

Patient must have the following:

WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)

AND ALL of the following:

a. Patient has had a clinical benefit from therapy (e.g., increased ANC or ALC or a reduction in infections)



Federal Employee Program.

XOLREMDI (mavorixafor)

b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Xolremdi and for 3 weeks after the last dose

Prior - Approval Renewal Limits

Same as above